A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors

[Crohn2357]

A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors
http://clinicaltrials.gov/show/NCT02100696
---
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
http://www.ncbi.nlm.nih.gov/pubmed/22717454
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
http://www.ncbi.nlm.nih.gov/pubmed/24814090
AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis
https://www.ecco-ibd.eu/index.php/p...te-to-severely-active-ulcerative-colitis.html